US20100241606A9 - Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples - Google Patents
Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples Download PDFInfo
- Publication number
- US20100241606A9 US20100241606A9 US10/448,379 US44837903A US2010241606A9 US 20100241606 A9 US20100241606 A9 US 20100241606A9 US 44837903 A US44837903 A US 44837903A US 2010241606 A9 US2010241606 A9 US 2010241606A9
- Authority
- US
- United States
- Prior art keywords
- variable
- saliva
- cortisol
- cort
- conc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Eye Examination Apparatus (AREA)
Abstract
Description
- The present invention relates to identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples, so as to determine the function of the hypothalamic-pituitary-adrenal (HPA) axis in individual subjects.
- The hypothalamus is a small, central part of the brain with several important regulatory functions, for example as regards physiologic response to external stress, bode weight (especially the metabolically unfavorable abdominal obesity), the sleep-wake cycle and mood fluctuations. As shown in
FIG. 1 , thehypothalamus 2 is connected to thepituitary 3 as part of the centralnervous system 1 and controls the secretion of different hormones from this endocrine gland. One of these hormones is ACTH (adenocorticotropic hormone), the secretion of which is activated through secretion of corticotropin releasing hormone (CRH) from thehypothalamus 2, as indicated byreference numeral 7 inFIG. 1 . In response, this will activate secretion of the stress-related hormone cortisol 6 from the cortex of the adrenal glands 5 (seereference numerals FIG. 1 ). - Cortisol 6 circulates in the bloodstream and activates specific receptors, such as the glucocorticoid receptor (GR), in another small part of the brain, the
hippocampus 4. This activation is indicated as 10 inFIG. 1 and leads to inhibition of the release of ACTH (reference numeral 11) as well as CRH (reference numeral 12). Thus a feedback loop is established, which regulates the blood concentration of cortisol. - The joint operation of the above functions, in the medical literature commonly referred to as the hypothalamic-pituitary-adrenal (HPA) axis, constitutes an important mechanism for maintaining steady state in the human organism. Disturbances in this mechanism have been shown to lead to metabolic complications, such as increased insulin resistance and abdominal obesity. These metabolic abnormalities are associated with increased risk for cardiovascular disease, the major cause of death in industrialized countries. A review of the above is found in “Neuroendocrine perturbations as a cause of insulin resistance” in Diabetes/Metabolism Research and Reviews 1999; 15:427-441, by Björntorp P. For a more detailed description see “Psychoneuroendocrine aspects on the metabolic syndrome”, ISBN 91-628-3195-X, by Rosmond R., Göteborg University 1993.
- Abnormal concentrations of cortisol have also been shown to be the biochemical mechanism for the influence of external stress factors on the metabolic system, which lead to increased risk for heart disease, in both humans and experimental animals.
- Since the concentration of this hormone in blood serum shows diurnal variation, the functional analysis of the HPA axis requires a number of cortisol measurements during the day, usually seven to ten, and may also have to be complemented by further examinations.
- The saliva level of cortisol is strongly correlated to the level in blood serum, as reported by Aardal E. and Holm AC. in “Cortisol in saliva—reference ranges and relation to cortisol in serum” in European Journal of Clinical Chemistry and Biochemistry 1995:33(12):927-32. Test equipment for measuring the amount of saliva cortisol, using Radio Immune Assays (RIA), are commercially available from Orion Diagnostica, Espoo, Finland and have been used to characterize the HPA axis in a population based study. However, the identification of abnormalities has up to now only been possible by means of statistical analysis of groups of subjects. Due to the large inter- and intra-individual variability, it has hitherto not been possible to classify individual subjects.
- Testosterone is the male sexual hormone but is present also in females, albeit in a very low concentration. This hormone interacts with cortisol in a fairly complex way, as described by Björntorp P. in “Hypothalamic origin of prevalent human disease” in “Hormones, Brain and Behaviour”, Academic Press, 2001 (in press), which can be summarized as follows:
- 1. In males low testosterone implies a more negative response to cortisol alteration, compared to the average or intermediate testosterone level. However, a high testosterone level also implies negative effects. Therefore, three levels of testosterone have to be defined, i.e. low, normal/intermediate and high. In males the gonads, i.e. the testicles, secrete most of the testosterone.
- 2. In females testosterone levels are normally low, i.e. testosterone may be close to zero without identifiable negative effects. However, testosterone levels in the upper quartile in a normal population are associated with increased risk for cardiovascular disease, and this relationship is stronger when cortisol levels are abnormal. It is assumed that the testosterone in females is secreted by the adrenal cortex, as is cortisol.
- In a recent study by Shifren J L, Braunstein G D, Simon J A, et al., “Transdermal testosterone treatment in women with impaired sexual function after oophorectomy”, N Engl J Med (United States), September 2000, 343(10) p 682-8, it was found that a certain (very low) level of testosterone may be necessary also for women, in order to maintain general well-being and a satisfying sex life.
- Testosterone can be measured in saliva, using the same principle as when measuring cortisol, as reported by Obminski Z and Stupnicki R in “Comparison of the testosterone-to-cortisol ratio values obtained from hormonal assays in saliva and serum” in J Sports Med Phys Fitness March 1997; 37(1):50-55, by Navarro M A et al. In “Salivary testosterone in postmenopausal women with rheumatoid arthritis”, J Rheumatol June 1998; 25(6):1059-62 and by Granger D A et al in “Salivary testosterone determination in studies of child health and development” in Horm Behav February 1999; 35(1):18-27.
- In view of the above shortcomings in the prior art, the present invention seeks to provide a method of identifying normal and abnormal diurnal cortisol secretion patterns from human saliva samples, specifically so that the function of the HPA axis may be determined for individual subjects in a convenient and completely structured manner with high accuracy.
- The objective is achieved through a computerized method of identifying normal and abnormal diurnal cortisol secretion patterns according to the attached independent patent claims. According to a preferred embodiment, only two measurements of saliva cortisol, compared to seven to ten measurements in the prior art, are performed during the same day at predetermined times. The two measurement values of saliva cortisol are input to a computer program, which will interpret the values by means of a fuzzy logic algorithm. The main output of the computer program is one of three possible classifications of the HPA axis function, i.e. normal, activated or blunted. The last two of these three classifications correspond to different levels of metabolic abnormalities and can be used by the tested individual as a basis for corrective measures or by physicians as a basis for therapeutic interventions.
- Advantageously, the first saliva sample is used also for determination of the testosterone level, which is analyzed in a similar manner.
- The use of the computer program according to the invention will not only for the first time allow determination of the function of the HPA axis for individual subjects rather than for an entire population; it will, moreover, provide considerable convenience, since only two saliva cortisol measurements are required for the determination of the diurnal cortisol pattern. In addition, the level of testosterone, which influences the evaluation of the HPA axis, can be measured simultaneously, wherein the computer program will use the measured testosterone value to further refine the evaluation of the HPA axis.
- The invention also guarantees a structured approach, since the HPA axis function will be determined in exactly the same way in every examination. Furthermore, the computer program quantifies the degree of membership in the particular classification group by means of a group membership index, which will allow an even more detailed analysis of the function of the HPA axis, as will be described in more detail in the following.
- Other objects, features and advantages of the present invention will appear from the following detailed disclosure, from the appended drawings as well as from the subclaims.
- A preferred embodiment and various other aspects of the present invention will now be described in more detail, reference being made to the accompanying drawings, in which:
-
FIG. 1 is a schematic illustration of the hypothalamic-pituitary-adrenal (HPA) axis, -
FIGS. 2 a-2 c are graphical representations of diurnal cortisol variation according to three different main categories of HPA axis function, -
FIG. 3 is a schematic overview of a computer system environment in which the computer program according to the invention may be executed, when used in an Internet application, -
FIG. 4 is a flowchart of the main steps of the method according to a preferred embodiment, -
FIG. 5 is a flowchart of an Internet use case for remote test and evaluation of diurnal cortisol secretion patterns from human saliva samples, and -
FIG. 6 is a graphical representation of a diurnal cortisol variation known as inverted HPA axis function. - As will be described in detail in the following, the main features of the invention involve:
- 1. The use of only two measurements of saliva cortisol concentration, sampled at defined times the same day.
- 2. A cortisol analysis algorithm, preferably implemented as a computer program, which analyses the measurement values and evaluates if the HPA axis function is normal or abnormal. If the HPA axis is abnormal, the program may also determine the type of abnormality.
- 3. Use of the above-mentioned computer program for remote distribution of tests and test results over the Internet.
- Preferably, the invention also involves a testosterone evaluation algorithm, advantageously implemented as part of the computer program, which evaluates the level of testosterone and integrates this information in the final determination of HPA axis abnormality.
- As stated above, the invention will make it possible to use saliva cortisol measurements, and optionally testosterone measurements, as a diagnostic tool in health care and for prevention of disease in the general population. Use of the Internet makes the test available to a large number of individuals.
-
FIGS. 2 a-2 c illustrate typical diurnal variations in saliva cortisol concentration according to the three different main categories of HPA axis function, i.e. normal, activated and blunted, respectively. The graphs illustrate typical concentration values, in nmol/dm3 (y axis), during seven different times of the day (denoted spit1 . . . spit7 on the x axis). Conventionally, as mentioned above, saliva cortisol concentration is measured at (at least) all these seven moments through the day. According to the invention, on the other hand, saliva cortisol concentration is only measured at the first and second of these different times of the day, i.e. at spit1 and spit2. Preferably, the two measurements are made at 07.00 am and 11.00 am, as shown inFIGS. 2 a-2c. - The test procedure will now be described with reference to
FIGS. 3 and 4 .FIG. 3 illustrate atest evaluation computer 20 having a central processing unit (CPU) 21, awork memory 22 such as a random access memory (RAM), and apermanent memory 23 such as a read-only memory (ROM) and/or a hard disk (HD). Thetest evaluation computer 20 has operative access to a database (DB) 24 for storing test results for a plurality of individuals, as will be described later with reference to an Internet use case. Thedatabase 24 may be stored locally in the test evaluation computer 20 (for instance in a portion of the permanent memory 23), but it may equally well be located externally to thecomputer 20. In the latter case, thecomputer 20 will preferably gain access to thedatabase 24 through local connection (serial or parallel interface, infrared interface, accessory bus, etc.) or through a networked connection to a local area network (LAN) or a wide area network (WAN), such as theInternet 50. - Additionally, the
computer 20 has input means 26 as well as output means 25. The input means 26 may comprise various different devices generally known per se, such as a keyboard, a mouse, or any type of digital data input interface (modem, ISDN, TCP/IP-based information exchange, etc). Correspondingly, the output means 25 may comprise various different known devices, such as a CRT display or an LCD display, a printer, or any type of digital data output interface (modem, ISDN, TCP/IP-based information exchange, etc). Generally, all hardware components of thetest evaluation computer 20 may be implemented by commercially available components, as is readily realized by a man skilled in the art. Moreover, thetest evaluation computer 20 is provided with a commercially available operating system, such as the Microsoft Windows family (e.g. NT), Unix (e.g. Linux), etc. - Next, with particular reference to
FIG. 4 a presently preferred embodiment of the test procedure will be described, where thetest evaluation computer 20 is used as a stand-alone computer. Another embodiment, where thetest evaluation computer 20 is used in an Internet application, will follow later. - Test Procedure
- 1. Saliva from the tested subject is obtained at 07.00 and 11.00, as indicated in
FIGS. 2 a-2 c, using conventional technique. - 2. The cortisol concentrations in the two test samples are measured in a conventional analysis machine, for instance one based on the above-mentioned RIA technique.
- 3. The testosterone level is determined for one of the saliva samples, preferably the first sample (07.00), using the same basic principle (for instance RIA technique) as when determining the cortisol concentrations.
- 4. The first and second measurement values are entered into the working
memory 22 of thecomputer 20 through its input means 26 (step 70 inFIG. 4 ). This may be performed either automatically using electronic communication between the analysis machine and the computer, or manually by the laboratory personnel using e.g. a keyboard and/or a mouse. Alternatively, particularly in an Internet application, the measurement values may be read from thetest database 24. - 5. The
permanent memory 23 is provided with a computer program comprising program code adapted to be read into the workingmemory 22 and executed by theprocessor 21 so as to perform the following test evaluation algorithm in an ordered sequence of operations and calculations: - First, in
step 70, two measurement variables,cort_conc —1 andcort_conc —2, are formed from the first and second measurement values, respectively. - Then, in a
step 71 the variables cort_conc—1 andcort_conc —2 are validated so as to eliminate obviously unrealistic values. If necessary, an error message is presented in astep 72, wherein the execution will terminate. - Otherwise, in a
step 73 the program calculates two analysis variables, namely cort_conc_slope, which is the difference between the first and second measurement variables (cort_conc —1 and cort_conc—2), and cort_conc_mean, which is the arithmetic mean of the variables cort_conc—1 andcort_conc —2. - A set of three constants, alpha, beta and gamma, is predefined in the program for each of the two analysis variables, i.e. cort_conc_slope and cort_conc_mean. These constants are retrieved in a
step 74. - Two indices, which are decimal numbers between 0.00 and 1.00, are calculated in a
step 75 for each variable. The first index, high_ind, defines to which degree the value of the variable can be regarded as high. The second index, low_ind, similarly defines to which degree the value of the variable can be regard as low. Preferably, it is calculated as the complement of high_ind (i.e., low_ind=1−high_ind). These index calculations are based on the three above-mentioned constants, alpha, beta and gamma, for each indexed variable. The values of these constants have been empirically derived before execution of the program. In one implementation made by the inventors the constants are based on a survey of the scientific literature combined with information from a study population, consisting of 550 randomly selected middle-aged Swedes. The constants are based on statistical correlations between the measurement values and the different types of HPA axis function. Correlations with metabolic and physiologic risk factors for heart disease were used to define the abnormalities of the HPA axis. - The constants, alpha, beta and gamma, are used in the following way in
step 75 when calculating the first index, high_ind, for each of the variables: - If the variable's value is lower than (or equal to) constant alpha, the index is set to 0.00.
- If the variable's is larger than (or equal to) constant gamma, the index is set to 1.00.
- If the variable's value is larger than constant alpha and smaller than (or equal to) constant beta, a program function calculates an index between 0.00 and 0.50. More specifically, the index is set to 2*(((x−alpha)/(gamma−alpha))2), where x is the value of the variable.
- If the variable's value is larger than (or equal to) constant beta and smaller than constant gamma, a program function calculates an index between 0.50 and 1.00. More specifically, the index is set to 1−(2* (((x−gamma)/(x−alpha))2)), where x is the value of the variable.
- The calculated indices are stored in a
step 76. - Each possible HPA axis is characterized by a particular combination of the calculated two indices. These combinations are defined in a basic group definition matrix:
Group Cort_conc_slope Cort_conc_mean Conclusion A High High Normal HPA axis B High Low Normal HPA axis C Low High Activated UPA axis D Low Low Blunted HPA axis - This matrix has four possible categories, labeled A-D. Categories A and B=normal HPA axis, category C=activated HPA axis, and category D=blunted HPA axis. The calculated indices from the tested individual are used to assign the individual to a particular classification group in the following way:
- A membership index is calculated for each classification group, as defined in the above table, by retrieving the lowest index value in the corresponding column of the group definition matrix, as shown in a
step 77. Thus, for each group (A-D) the membership index is defined as min(index_for_cort_conc_slope, index_for_cort_conc_mean). This minimum value is stored in astep 78. - Then, the tested subject is assigned to the group with the highest membership index in a
step 79. - The above may be exemplified as follows:
- In a normal subject, the value of cort_conc_slope should be high and the value of cort_conc_mean may be either high or low. This appears from the leftmost portion of the graph in
FIG. 2 a. - The corresponding indices for a subject could then be as follows:
- The high_index for cort_conc_slope might be 1.00 (corresponds to a high test value in the morning sample at 07.00 am and a low test value in the second sample at 11.00).
- The high_ind for cort_conc_mean might be 0.6.
- This subject belongs to the group with normal HPA axis (group A in the group definition matrix) with a membership value of 0.6 (i.e. the minimum of 1.00 and 0.6). The membership value of any other group would be less than this value.
- Borderline cases, i.e. two classification groups with identical membership indices, may occur. These subjects are labeled as borderline normal/activated, borderline normal/-blunted or borderline activated/blunted as appropriate with regard to the indices.
- In a
step 80, once the program has been able to either determine a single classification group for the subject, or a borderline case as described above, the result is output through the output means 25. - The evaluation is refined by the addition of the information about testosterone level. The testosterone value is evaluated as follows:
- 1. In males: If the value is below a threshold value, the level is labeled as low. If the value is above this threshold value, the level is labeled normal.
- 2. In females: If the testosterone value is above a threshold value it is labeled high, otherwise it is labeled normal.
- Advantageously, the program is adapted to evaluate whether the second cortisol concentration (cort_conc—2) is higher than the first cortisol concentration (cort_conc—1). Such a situation will be labeled as inverted HPA axis and is illustrated in
FIG. 6 . This abnormality is associated with disturbed sleep pattern and/or diurnal rhythm. - Internet Use
- The procedure described above may preferably be used over the Internet, as will be explained with reference to
FIGS. 3 and 5 . - 1. The customer (user 30) uses a
web client 31 to access a web site on aweb server 27, which presents relevant information. - 2. The customer orders a test kit (see dot and dash line i in
FIG. 3 ) and pays using a standard electronic payment procedure, which is not described further herein. - 3. The customer receives a test kit to his/her address, using standard postal delivery 60 (see line ii in
FIG. 3 ). This test kit contains an ID code, which is unique for each test kit. - 4. The customer sends the test kit, which now contains the first and second saliva samples, to a contracted
laboratory 40, using a preaddressed envelope, delivered to the customer together with the test kit. See line iii inFIG. 3 . - 5. The laboratory performs the analyses and reports the results together with the test ID to the
test database 24, which is connected to theweb server 27 and thetest computer 20. See line iv inFIG. 3 . - 6. The customer accesses the web site a second time and enters the test kit ID code. The program described above retrieves the test results from the database by means of the ID code, performs the evaluation as described above and presents the conclusion to the customer, who has the option to obtain a print-out if he/she so wishes. See line v in
FIG. 3 . Preferably, the conclusion involves not only the results from the measurement evaluation (i.e. the determined category of HPA axis functionality) but also a prediction of the risk of deranged health for the customer. - The flow is depicted in
FIG. 5 and may be carried out for cortisol concentration measurements only, for both cortisol concentration measurements and a testosterone measurement, or for a testosterone measurement alone. At present, however, a combination of cortisol concentration measurements and a testosterone measurement is believed to provide the highest accuracy in the analysis of the HPA axis function and the prediction of the risk of deranged health for the customer. - Program Implementation
- An embodiment of the described program is implemented using the syntax module in Statistical Package for Social Sciences (SPSS) and also using VBScript for use over the Internet. The program can, however, be implemented in any other general purpose programming or scripting language, including but not limited to C++, Java, Visual Basic, Delphi or JavaScript.
- Program Validation
- Program output has been compared to actual measurement values (seven each day) from the study population mentioned above. The program clearly identified the three main types of HPA axis diurnal pattern, see
FIGS. 2 a-2 c, using only two of the saliva cortisol measurements (at 07.00 am and 11.00 am). - The classifications (in three main categories) have been compared to the outcomes of associated tests regarding saliva cortisol. These tests are:
- 1. Response to a standardized lunch. Food induces an increase in blood and saliva cortisol. This increase can be measured by repeated tests and used as an aid in the determination of the function of the HPA axis in a particular individual.
- 2. Dexamethason suppression test. Dexamethason is a synthetic substance, essentially identical with the cortisol, secreted from the adrenal glands. When dexamethason is administered in the form of pills, the blood and saliva cortisol is decreased. The rate of decrease can be measured by repeated tests and used as an aid in the determination of the function of the HPA axis in a particular individual.
- The correlations between the results from these two associated tests and the classification performed by the computer program were very good, indicating that the same information was established using the program's analysis of only two tests compared to the conventional method, using statistical analysis of seven tests.
- The classifications (in three main categories) were also compared to known risk factors for heart disease and significant associations were observed. One example is insulin resistance (s-insulin/s-glucose quotient) in males, which was higher in the groups with abnormal HPA axis. Hence, the method apparently identifies individuals with rather discrete deviations from normality.
- The evaluation is further refined by the addition of the information about testosterone levels. This results in a doubling of the number of groups, since the testosterone value may be either normal or abnormal, i.e. abnormal when high in women or low in men, and otherwise normal.
- Advantages
- The invention allows determination of the functional state of the HPA axis, based on only two measurements of the concentration of cortisol in saliva, performed the same day at defined times, optionally in addition to one simultaneously performed measurement of testosterone level in saliva. A computer program performs the interpretation of the test results. The invention facilitates practical use of measurements of saliva cortisol for determination of the function of the HPA axis, since only two saliva tests are needed from each subject. The use of a computer program for evaluation of the measurement values guarantees that all subjects are evaluated in an identical way in all examinations. The derangements in HPA axis function, identified by the program, are relevant for the health of individual subjects, and the computer-based analysis of the measurement values gives new information, hitherto not available. Use over the Internet provides access to the system to a large number of individuals. The addition of testosterone values improves the relationship between the diagnostic groups and risk factors for e.g. cardiovascular disease.
- The present invention has been described above with reference to a preferred embodiment. However, other embodiments than the one disclosed above are equally possible within the scope of the invention, as defined by the attached independent patent claims.
Claims (17)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0004461A SE517528C2 (en) | 2000-12-04 | 2000-12-04 | Computerized identification of normal and abnormal daily patterns for cortisol secretion and testosterone levels from human saliva samples |
SE0004461 | 2000-12-04 | ||
SE0004461.0 | 2000-12-04 | ||
SEPCT/SE01/02670 | 2001-12-04 | ||
PCT/SE2001/002670 WO2002046771A1 (en) | 2000-12-04 | 2001-12-04 | Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples |
WOPCT/SE01/02670 | 2002-01-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2001/002670 Continuation WO2002046771A1 (en) | 2000-12-04 | 2001-12-04 | Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples |
Publications (3)
Publication Number | Publication Date |
---|---|
US20040039719A1 US20040039719A1 (en) | 2004-02-26 |
US20100241606A9 true US20100241606A9 (en) | 2010-09-23 |
US7805396B2 US7805396B2 (en) | 2010-09-28 |
Family
ID=20282077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/448,379 Expired - Fee Related US7805396B2 (en) | 2000-12-04 | 2003-05-30 | Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples |
Country Status (7)
Country | Link |
---|---|
US (1) | US7805396B2 (en) |
EP (1) | EP1340089B1 (en) |
JP (1) | JP2004515765A (en) |
AT (1) | ATE370417T1 (en) |
DE (1) | DE60130020T2 (en) |
SE (1) | SE517528C2 (en) |
WO (1) | WO2002046771A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080281166A1 (en) * | 2007-05-10 | 2008-11-13 | Advanced Breath Diagnostics, Llc | Methods and systems for assessing gastric emptying |
US10772534B2 (en) | 2013-03-13 | 2020-09-15 | Advanced Breath Diagnostics, Llc | Single-point gastric emptying breath tests |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060129590A1 (en) * | 2004-12-10 | 2006-06-15 | Aoki-Rice Companies | Method and medium for managing data |
KR101029251B1 (en) | 2009-06-18 | 2011-04-18 | 전남대학교산학협력단 | Evaluation Method and Evaluation Indicator of Cortisol Diurnal Rhythm by Determination of Salivary Cortisol |
US8311973B1 (en) | 2011-09-24 | 2012-11-13 | Zadeh Lotfi A | Methods and systems for applications for Z-numbers |
US11074495B2 (en) | 2013-02-28 | 2021-07-27 | Z Advanced Computing, Inc. (Zac) | System and method for extremely efficient image and pattern recognition and artificial intelligence platform |
US9916538B2 (en) | 2012-09-15 | 2018-03-13 | Z Advanced Computing, Inc. | Method and system for feature detection |
US11195057B2 (en) | 2014-03-18 | 2021-12-07 | Z Advanced Computing, Inc. | System and method for extremely efficient image and pattern recognition and artificial intelligence platform |
US11914674B2 (en) | 2011-09-24 | 2024-02-27 | Z Advanced Computing, Inc. | System and method for extremely efficient image and pattern recognition and artificial intelligence platform |
US8873813B2 (en) | 2012-09-17 | 2014-10-28 | Z Advanced Computing, Inc. | Application of Z-webs and Z-factors to analytics, search engine, learning, recognition, natural language, and other utilities |
KR101444235B1 (en) * | 2012-07-17 | 2014-09-26 | 주식회사 피코팜 | A Diagnosis Method of Complex Regional Pain Syndrome Type 1 Using Correlation of Hypothalamic pituitary adrenal axis function |
KR102404986B1 (en) * | 2022-01-20 | 2022-06-07 | (주) 마인즈에이아이 | A Method for providing information for an andropause diagnosis and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5788640A (en) * | 1995-10-26 | 1998-08-04 | Peters; Robert Mitchell | System and method for performing fuzzy cluster classification of stress tests |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2294294A1 (en) * | 1997-07-14 | 1999-01-28 | Abbott Laboratories | Telemedicine |
JPH1138004A (en) * | 1997-07-16 | 1999-02-12 | Pola Chem Ind Inc | Quantifying method for stress |
JP3108765B2 (en) * | 1999-03-24 | 2000-11-13 | 工業技術院長 | Chronic stress determination method and device, recording medium, determination sheet |
-
2000
- 2000-12-04 SE SE0004461A patent/SE517528C2/en not_active IP Right Cessation
-
2001
- 2001-12-04 WO PCT/SE2001/002670 patent/WO2002046771A1/en active IP Right Grant
- 2001-12-04 DE DE60130020T patent/DE60130020T2/en not_active Expired - Lifetime
- 2001-12-04 EP EP01999819A patent/EP1340089B1/en not_active Expired - Lifetime
- 2001-12-04 AT AT01999819T patent/ATE370417T1/en not_active IP Right Cessation
- 2001-12-04 JP JP2002548457A patent/JP2004515765A/en active Pending
-
2003
- 2003-05-30 US US10/448,379 patent/US7805396B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5788640A (en) * | 1995-10-26 | 1998-08-04 | Peters; Robert Mitchell | System and method for performing fuzzy cluster classification of stress tests |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080281166A1 (en) * | 2007-05-10 | 2008-11-13 | Advanced Breath Diagnostics, Llc | Methods and systems for assessing gastric emptying |
US8231530B2 (en) * | 2007-05-10 | 2012-07-31 | Advanced Breath Diagnostics, Llc | Methods and systems for assessing gastric emptying |
US8388531B2 (en) | 2007-05-10 | 2013-03-05 | Advanced Breath Diagnostics, Llc | Methods and systems for assessing gastric emptying |
US10772534B2 (en) | 2013-03-13 | 2020-09-15 | Advanced Breath Diagnostics, Llc | Single-point gastric emptying breath tests |
Also Published As
Publication number | Publication date |
---|---|
US20040039719A1 (en) | 2004-02-26 |
SE517528C2 (en) | 2002-06-18 |
EP1340089B1 (en) | 2007-08-15 |
DE60130020D1 (en) | 2007-09-27 |
US7805396B2 (en) | 2010-09-28 |
JP2004515765A (en) | 2004-05-27 |
WO2002046771A1 (en) | 2002-06-13 |
DE60130020T2 (en) | 2008-05-08 |
SE0004461L (en) | 2002-06-05 |
ATE370417T1 (en) | 2007-09-15 |
SE0004461D0 (en) | 2000-12-04 |
EP1340089A1 (en) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7805396B2 (en) | Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples | |
Weissman et al. | Gender and depression | |
US7647234B1 (en) | Cardiovascular healthcare management system and method | |
Randolph Jr et al. | The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition | |
US6572564B2 (en) | Method of providing a home health care service and system for providing a home health care service | |
Seplaki et al. | Measurement of cumulative physiological dysregulation in an older population | |
US20030125609A1 (en) | Method for reliable measurement in medical care and patient self monitoring | |
Hlatky et al. | Tying clinical research to patient care by use of an observational database | |
US20120101846A1 (en) | Computer-Implemented Method For Displaying Patient-Related Diagnoses Of Chronic Illnesses | |
US20030208108A1 (en) | Cardiovascular healthcare management system and method | |
JP2002022748A (en) | Clinical inspection system | |
EP1206212A1 (en) | Chronic disease monitor | |
US20120130743A1 (en) | Computer-Implemented Method for Medical Diagnosis Support | |
JP2008547078A (en) | Living body age measuring apparatus and service method thereof | |
Jørgensen et al. | Plasma glucose reference intervalin a low-risk population. 2. Impact ofthe new WHO and ADA recommendations on the diagnosis of diabetes mellitus | |
Livingston et al. | Is a fasting testosterone level really necessary for the determination of androgen status in men? | |
Christensen et al. | Masculinising testosterone treatment and effects on preclinical cardiovascular disease, muscle strength and power, aggression, physical fitness and respiratory function in transgender men: protocol for a 10-year, prospective, observational cohort study in Denmark at the Body Identity Clinic (BIC) | |
CN115620900B (en) | System and method for screening polycystic ovary syndrome | |
Michaelidou et al. | Recalibration of thinking about adrenocortical function assessment: how the ‘random’cortisol relates to the short synacthen test results | |
Frank et al. | Adolescent BMI trajectory and associations with adult metabolic syndrome and offspring obesity | |
Sarasin | Decision analysis and its application in clinical medicine | |
Zoaktafi et al. | Relationship between mental workload and salivary cortisol levels: A field study | |
JP2002014095A (en) | System and method for analyzing and displaying blood test data | |
JP2003526137A (en) | Method and apparatus for automatically allocating staffing | |
Moorthy et al. | Phenotyping of Indian Polycystic Ovarian Syndrome on the basis of Biochemical Parameters: A retrospective analysis via Hierarchical Cluster Classification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DIAGNO-INTERNATIONAL BV, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WAGNER, PETER;MARTIN, LENE;REEL/FRAME:014582/0069 Effective date: 20031001 |
|
CC | Certificate of correction | ||
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
REIN | Reinstatement after maintenance fee payment confirmed | ||
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140928 |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES DISMISSED (ORIGINAL EVENT CODE: PMFS); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
PRDP | Patent reinstated due to the acceptance of a late maintenance fee |
Effective date: 20151210 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
SULP | Surcharge for late payment | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220928 |